This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
by Aparajita Dutta
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
AMGNPositive Net Change ILMNNegative Net Change MRNAPositive Net Change HALONegative Net Change BBHPositive Net Change FBTPositive Net Change BBPNegative Net Change IOVAPositive Net Change
biotechnology biotechs etfs
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
by Zacks Equity Research
NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
NVSPositive Net Change RGENNegative Net Change ANIKPositive Net Change IONSPositive Net Change
biotechnology biotechs pharmaceuticals
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
by Ekta Bagri
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
BMYPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU
by Zacks Equity Research
NVO's Sogroya wins a positive CHMP opinion for idiopathic short stature in the EU, potentially broadening its pediatric growth disorder reach.
NVOPositive Net Change ALDXNegative Net Change ACIUNegative Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
by Ekta Bagri
Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.
BMYPositive Net Change AMGNPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
by Zacks Equity Research
AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.
AZNPositive Net Change BMRNNegative Net Change RXRXNegative Net Change
biotechs medical pharmaceuticals
4 Biotech Stocks to Watch as Potential Takeover Targets
by Sundeep Ganoria
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
BCRXPositive Net Change VKTXNegative Net Change IOVAPositive Net Change ABVXNegative Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
by Zacks Equity Research
Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.
RARENegative Net Change ALDXNegative Net Change ACIUNegative Net Change PGENPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
by Zacks Equity Research
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
PBYINegative Net Change RGENNegative Net Change ANIKPositive Net Change PGENPositive Net Change
biotechs
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
by Kanishka Das
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
NTLANegative Net Change REGNNegative Net Change BEAMNegative Net Change CRSPNegative Net Change
biotechs